Sort by
Previous Page Page 2 of 2 Next Page
  1. Review

    Immunotherapy in endometrial cancer - an evolving therapeutic paradigm

    Endometrial cancer is the only gynecologic malignancy with a rising incidence and mortality. While cure is routinely achieved with surgery alone or in combination with adjuvant pelvic radiotherapy when disease...

    Teresa C. Longoria and Ramez N. Eskander

    Gynecologic Oncology Research and Practice 2015 2:11

    Published on: 2 December 2015

    The Erratum to this article has been published in Gynecologic Oncology Research and Practice 2016 3:2

  2. Research

    Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience

    Early-stage vaginal and vulvar cancer can be cured. But outcomes of patients with metastatic disease are poor. Thus, new therapeutic strategies are urgently required.

    Siqing Fu, Naiyi Shi, Jennifer Wheler, Aung Naing, Filip Janku, Sarina Piha-Paul, Jing Gong, David Hong, Apostolia Tsimberidou, Ralph Zinner, Vivek Subbiah, Ming-Mo Hou, Pedro Ramirez, Lois Ramondetta, Karen Lu and Funda Meric-Bernstam

    Gynecologic Oncology Research and Practice 2015 2:10

    Published on: 14 November 2015

  3. Research

    Clinico-epidemiological profile of molar pregnancies in a tertiary care centre of Eastern Nepal: a retrospective review of medical records

    The incidence of molar pregnancy has demonstrated marked geographic and ethnic differences. The reported data in Nepal is inconsistent with minimal published literature. Thus, we designed a study to determine ...

    Nimisha Agrawal, Reshu Agrawal Sagtani, Shyam Sundar Budhathoki and Hanoon P. Pokharel

    Gynecologic Oncology Research and Practice 2015 2:9

    Published on: 31 October 2015

  4. Case report

    Impact of cervical cancer on quality of life: beyond the short term (Results from a single institution)

    Cervical cancer (CC) is one of the most widespread gynecological malignancies in women worldwide. Treatment strategies and screening modalities have largely evolved these past years resulting in an improvement...

    J. Khalil, S. Bellefqih, N. Sahli, M. Afif, H. Elkacemi, S. Elmajjaoui, T. Kebdani and N. Benjaafar

    Gynecologic Oncology Research and Practice 2015 2:7

    Published on: 19 September 2015

  5. Research

    Willingness and acceptability of cervical cancer screening among women living with HIV/AIDS in Addis Ababa, Ethiopia: a cross sectional study

    In Ethiopia, cervical cancer (CC) ranks the 2nd most frequent cancer and the country had 27.19 million women at risk of developing the disease though only 0.6 % women age 18-69 years was screened every 3 years...

    Netsanet Belete, Yosief Tsige and Habtamu Mellie

    Gynecologic Oncology Research and Practice 2015 2:6

    Published on: 18 September 2015

  6. Review

    Opportunistic salpingectomy for ovarian cancer prevention

    Recently accumulated evidence has strongly indicated that the fallopian tube is the site of origin for the majority of high-grade serous ovarian or peritoneal carcinomas. As a result, recommendations have been...

    Gillian E. Hanley, Jessica N. McAlpine, Janice S. Kwon and Gillian Mitchell

    Gynecologic Oncology Research and Practice 2015 2:5

    Published on: 17 September 2015

  7. Case report

    Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease

    Compared to other subtypes of epithelial ovarian cancer, clear cell carcinoma of the ovary bears an ominous reputation for chemotherapy resistance, increased relapse rate, and diminished survival. Among patien...

    Michael P. Castro, Bradford P. Whitcomb, Deborah A. Zajchowski and Robert L. Coleman

    Gynecologic Oncology Research and Practice 2015 2:4

    Published on: 28 August 2015

  8. Research

    Diagnostic, therapeutic and evolutionary characteristics of cervical cancer in Department of Radiotherapy, Mohamed V Military Hospital – Rabat in Morocco

    Cancer of uterine cervix is the second most common cause of cancer related deaths among women. The aim of this study is to report the experience of Military Hospital Mohamed V in the management of cervical can...

    Mohammed Elmarjany, Abdelhak Maghous, Rachid Razine, Elamin Marnouche, Khalid Andaloussi, Amine Bazine, Issam Lalya, Noha Zaghba, Khalid Hadadi, Hassan Sifat, Baba Habib, Jaouad Kouach and Hamid Mansouri

    Gynecologic Oncology Research and Practice 2015 2:2

    Published on: 27 July 2015

  9. Case report

    Very late recurrence of Diethylstilbestrol - related clear cell carcinoma of the cervix: case report

    Clear cell adenocarcinoma of the cervix is a rare tumor of the lower genital tract. It has been described in young women with a history of intra uterine exposure to diethylstilbestrol. This tumor is characteri...

    Ablavi Adani-Ifè, Emma Goldschmidt, Pasquale Innominato, Ayhan Ulusakarya, Hassan Errihani, Philippe Bertheau and Jean François Morère

    Gynecologic Oncology Research and Practice 2015 2:3

    Published on: 17 July 2015

  10. Review

    Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms

    Traditionally, epithelial ovarian, tubal, and peritoneal cancers have been viewed as separate entities with disparate origins, pathogenesis, clinical features, and outcomes. Additionally, previous classificati...

    Lauren Patterson Cobb, Stephanie Gaillard, Yihong Wang, Ie-Ming Shih and Angeles Alvarez Secord

    Gynecologic Oncology Research and Practice 2015 2:1

    Published on: 12 May 2015

  11. Case report

    Differentiating pelvic actinomycosis from advanced ovarian cancer: a report of two cases, management reflections and literature review

    Pelvic actinomycosis comprises a rare, subacute to chronic bacterial infection characterised by suppurative and granulomatous inflammation. Diagnosis is difficult as it may simulate pelvic malignancies. Labora...

    Alex Laios, Iryna Terekh, Hooman Soleymani Majd, Pubudu Pathiraja, Sanjiv Manek and Krishnayan Haldar

    Gynecologic Oncology Research and Practice 2014 1:5

    Published on: 10 December 2014

  12. Research

    In vitro chemoresponse in metachronous pairs of gyneclologic cancers

    While most gynecologic cancers respond to first-line cytotoxic chemotherapy, treatment of recurrent disease is frequently associated with acquired drug resistance. In order to find an in vitro surrogate of thi...

    Heather J Dalton, James Fiorica, Candace K McClure, Rodney P Rocconi, Fernando O Recio, John L Levocchio, Matthew O Burrell and Bradley J Monk

    Gynecologic Oncology Research and Practice 2014 1:7

    Published on: 6 December 2014

  13. Case report

    Uterine cervix metastasis from a sigmoid adenocarcinoma: a rare presentation of an uncommon tumor

    Metastatic carcinoma to the uterine cervix from colorectal cancer, through haematogenous or lymphatic spread, is extremely rare. We report the case of a 59 year old woman in whom cervical metastasis was diagno...

    Soufiane Berhili, Basma El Khannoussi, Selma Kadiri, Imane Mezouri, Amine Bazine, Asmae Touil, Imane El Khiyat, Tayeb Kebdani and Noureddine Benjaafar

    Gynecologic Oncology Research and Practice 2014 1:6

    Published on: 1 December 2014

  14. Research

    Dasatinib (BMS-35482) potentiates the activity of gemcitabine and docetaxel in uterine leiomyosarcoma cell lines

    To explore the activity of dasatinib alone and in combination with gemcitabine and docetaxel in uterine leiomyosarcoma (uLMS) cell lines, and determine if dasatinib inhibits the SRC pathway.

    Micael Lopez-Acevedo, Lisa Grace, Deanna Teoh, Regina Whitaker, David J Adams, Jingquan Jia, Andrew B Nixon and Angeles Alvarez Secord

    Gynecologic Oncology Research and Practice 2014 1:2

    Published on: 30 September 2014

  15. Review

    Updates on drug discovery in ovarian cancer

    Drug discovery in the ovarian cancer arena continues to launch important new clinical trials. Many biologic agents are being studied in phase II and phase III clinical trials for recurrent disease. These agent...

    Steven J Gibson, Krishnansu S Tewari, Bradley J Monk and Dana M Chase

    Gynecologic Oncology Research and Practice 2014 1:3

    Published on: 30 September 2014

Previous Page Page 2 of 2 Next Page